-
Sign up now for AHC Media's upcoming audio conference, The Buck Stops Soon: Prevent CR-BSIs or Pay Up on Thursday, March 26, 2008, from 1 p.m-2:30 p.m. ET.
-
The Joint Commission has broadly expanded its emphasis on infection prevention in proposed 2009 patient safety goals that recommend specific strategies to fight a veritable "murderers' row" of health care-associated infections (HAIs).
-
The Centers for Disease Control and Prevention in conjunction with Kaiser Permanente's Northern California Division of Research will formally investigate an unexplained but persistently reported skin condition known as Morgellons.
-
A recent controversial move by a federal health agency to shut down a highly successful infection prevention program because it appeared to be involved in human research rather than quality improvement has ominous implications for traditional infection control activities, a leading epidemiologist tells Hospital Infection Control.
-
The Michigan Health & Hospital Association's Keystone Center for Patient Safety & Quality has created a "bladder bundle" of measures to prevent urinary tract infections. Some of the key recommendations for implementation of the bundle are summarized as follows:
-
Recall of a dozen lots of two Haemophilus influenzae type b (Hib) vaccines and suspension of production by a major manufacturer will result in a national shortage that could put children at risk and will certainly trouble physicians and parents in the short run, Julie Gerberding, MD, MPH, director of the Centers for Disease Control and Prevention, warns.
-
Though they are the most common infectious complication in hospitals, urinary tract infections (UTIs) get no respect.
-
Merck & Co. has initiated a voluntary recall in the United States for 10 lots of PedvaxHIB® [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] and two lots of COMVAX® [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine].
-
All the planets appear to be lining up to make a persuasive "business case" for infection control.
-
Regardless of the current controversy regarding the efficacy of seasonal influenza vaccination in the elderly, it seems a given that seniors will fare much worse should a pandemic strain arise that eludes an immune response in all ages. But under closer scrutiny, that logic does not hold.